AstraZeneca prevailed on its argument that patents-in-suit are invalid because they are not enabled on the issue of unit dosage.
August 15, 2024 at 05:34 PM
4 minute read
AstraZeneca Pharmaceuticals LP, arguing posttrial against a jury finding that two of plaintiffs’ patents were valid, got an opposite finding, erasing a $107.5 million verdict.
At conclusion of a five-day jury trial in May in the U.S. District Court for the District of Delaware, a jury found AstraZeneca infringed on two patents held by Wyeth LLC, a Pfizer subsidiary.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
The Texas Lawyer honors attorneys and judges who have made a remarkable difference in the legal profession in Texas.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
The Forest Preserves of Cook CountyIs seeking applicants forDeputy Chief Attorney The Forest Preserves of Cook County is seeking a detail-o...
McCarter & English, LLP is actively seeking an associate the to join its Environment & Energy Practice Group in Newark, NJ. Candida...
